Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Good.orning Damion,
A very pertinent post with link to.
Importantly SDC1802 granted further protection with patent for application in autoimmune.
Takeda 4 billion paid for Tyk2 inhibitor at phase2 stage.
If we took a modest risk factor and at one tenth of the price that equate to 400 million around 450p per share.
Raise additional funds for phase 2 or licence towards end of year.
Clearly the multiple ascending dose data is of the upmost importance.
All important LADMET information from human trials.
Very difficult to give an accurate prediction in preclinical even when 3 different animals involved but we can be reassured due to Deucravacitinib approved for use.
As for the remainder of the Jaks we can look at Baricitinib and although with black box warnings we have far greater selectivity of Jak1 over Jak2 and in addition we have a 4 to 5 fold selectivity of Tyk2 over Jak1.
According to Tim as he termed ,' we believe to be the optimal.amount'
I am certain 300k raise will be over subscribed.
I dont know if the HNWI'S will partake in this, but l not think that will make any difference if they do not.
All important safety data results can then be given to the interested parties.
When this is recieved the interested parties along with Tim and Co can discuss licensing deals or options and is the key time when formal offers leading to an on licence to occur.
Tim and Co here will have option to finance via fund raise or on licence.
Preferably l would like to see Sareum take 1801 into phase 2a first.
Regards
Warthog4,
Wish and pray that you will get well soon to keep this board alive.
Hi Warty hope you op goes well and you have a speedy recovery. LH&K Mafuta
Best of luck with your op warty.
Hope you will soon be back up and running
Good luck with the surgery tomorrow!
2024 Anticipated Milestones
SDC-1801: Clinical development roadmap
Multiple Ascending Dose (MAD) and topline data analysis expected to complete in Q2
Assess options for further financing or SDC-1801 licence in Q3
Potential for phase 2a trial in psoriasis patents or SDC-1801 licence from Q4
+ potential for (timing unknown)
SRA737 Update
Share of $1M milestone payment, identification of US partner, clinical plans ($1 million due within 12 months or on licensee’s funding milestone)
https://sareum.com/wp-content/uploads/2024/03/Sareum-Company-March-2024-for-website.pdf
-----------
All the the best with your op 2morro warty
Wishing you well Warty and a speedy recovery, it will take time of course.
Keep us updated here.
Regards
Hang in there, Warty, you'll be fine. Anyone who has remained invested in Sareum as long as you have (with all the trials and tribulations associated therein), has the resolve to overcome anything! Best wishes.
That gave me a good chuckle, keep up the spirit. Good luck for tomorrow.
Thanks for all your kind messages. Now lunchtime
Easter Day and a real blast. Bollinger flowing like water,dancing in the corridors, and all the patients singing along. In my dreams of course-
In reality It is more like Temperance HQ during
Happy Hour
Under the knife tomorrow Bw-watch this space
Thanks again
GLA
So not an MK franchise fan then?
Forgot to say. P.u.P.. ⚽️🏆👍
Get every £1 that you have then, did you get your Crystal ball off Amazon ?
Hello W4. I feel your pain. I’m a Portsmouth season ticket holder and go to most away games. When leaving Peterborough stadium two weeks ago (won1-0) leather soled shoes and wet stairs saw me go down six or eight of them. Got a lump on my hip / leg bigger than Katie Price’s left t!t. Was able to walk so refused a+e as couldn’t confront a day waiting to be seen. 😩. Hope you get out the hospital soon as for sure you’ll come out with more than you went in with.
On a separate note I think anyone buying at current prices is sure to make money. People always asked how LTH’s made money in the past. Simples. Buy when Sar are on their @r$e and then be patient. But make sure to take the profits when they’re there. Gla. Andy. 😀
That is what i now think they are headed. 5p?
Yes but discharged as hipless cases HaHa
Matty,it will be. It will be to my advantage if the smaller requests are met in full or everyone is allocated a modest maximum.
Sorry to hear of your troubles Warty - wishing you well and a speedy recovery.
Get well soon warty!
Get well soon
KR
ZA
Hi Ben/Num4 - I only floated the idea of doing the trial in the UK as the Nucleus Network don't appear to do P2a trials, their focus seems to be P1 (see first link below).
https://www.parexel.com/application/files/resources/assets/Australia%20Clinical%20Trials%20Article_Second%20in%20a%20three-part%20series%20(1).pdf
This other link might be interesting to some as it talks about pricing strategies (not that we're anywhere near that point yet but interesting all the same).
https://www.parexel.com/application/files/resources/assets/Australia%20Regulatory%20Market%20Access%20Article_Third%20in%20a%20three-part%20series%20(1).pdf
Yeah, the working capital these US companies must require is huge. When I was poking about the US SEC.gov website for 737 info I came across the Sierra announcement that it was paying their chief exec something like $400k a year plus options (and this was before the GSK merger).
Glen.
OMG so v close to the truth- I WAS heading for the wine section but never got there!
Thimk there is a metaphor or two that would sum up a return to the mercy of the MHRA. Once bitten, twice shy. Or what about another, fool me once shame on you, fool me twice shame on me.